T 0098/24 (Liposomal irinotecan II/IPSEN) of 27.01.2026
- European Case Law Identifier
- ECLI:EP:BA:2026:T009824.20260127
- Date of decision
- 27 January 2026
- Case number
- T 0098/24
- Petition for review of
- -
- Application number
- 17169098.5
- IPC class
- A61K 45/06A61K 31/519A61P 43/00A61P 1/18A61P 35/00A61K 9/00A61P 9/00A61K 31/4745A61K 31/513A61K 9/127
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- COMBINATIONS OF LIPOSOMAL IRINOTECAN, 5-FU AND LEUCOVORIN FOR THE TREATMENT OF PANCREATIC CANCER
- Applicant name
- Ipsen Biopharm Ltd.
- Opponent name
- Sandoz AG
Teva Pharmaceutical Industries Ltd.
Generics [UK] Limited - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 76(1)Rules of procedure of the Boards of Appeal Art 12(6)
- Keywords
- Divisional application - added subject-matter (yes)
Late-filed evidence - should have been submitted in first-instance proceedings (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.